Show simple item record

dc.contributor.authorSchütte, J
dc.contributor.authorMouridsen, H T
dc.contributor.authorStewart, Wendy
dc.contributor.authorSantoro, A
dc.contributor.authorVan Oosterom, A T
dc.contributor.authorSomers, R
dc.contributor.authorBlackledge, G
dc.contributor.authorVerweij, J
dc.contributor.authorDombernowsky, P
dc.contributor.authorThomas, D
dc.date.accessioned2010-08-17T09:38:03Z
dc.date.available2010-08-17T09:38:03Z
dc.date.issued1990
dc.identifier.citationIfosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. 1990, 26 (5):558-61 Eur. J. Canceren
dc.identifier.issn0959-8049
dc.identifier.pmid2144740
dc.identifier.urihttp://hdl.handle.net/10541/109723
dc.description.abstractThe objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma. Treatment was doxorubicin 50 mg/m2 followed by a 24 h infusion of ifosfamide 5 g/m2 plus mesna 2.5 g/m2 repeated every 3 weeks until disease progression or unacceptable toxicity occurred. Of 203 patients entered, 175 were evaluable for response. The response rate was 35% (95% CI 28-42%), with 9% of the patients achieving a complete remission and 26% a partial remission. The median time to progression was 29 weeks for all evaluable patients, and 67, 40 and 28 weeks for complete and partial responders and patients with stable disease, respectively. The median duration of survival was 58 weeks. Myelosuppression was the dose-limiting toxicity, resulting in leukopenia (WHO grade 3 and 4) in 73% of evaluable treatment courses. Other side-effects were rare and usually well manageable.
dc.language.isoenen
dc.subjectSoft Tissue Canceren
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshDoxorubicin
dc.subject.meshDrug Evaluation
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshIfosfamide
dc.subject.meshLeukopenia
dc.subject.meshMale
dc.subject.meshMesna
dc.subject.meshMiddle Aged
dc.subject.meshSarcoma
dc.subject.meshSoft Tissue Neoplasms
dc.subject.meshThrombocytopenia
dc.titleIfosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.en
dc.typeArticleen
dc.contributor.departmentInnere Klinik und Poliklinik, Universitatsklinikum Essen, F.R.G.en
dc.identifier.journalEuropean Journal of Canceren
html.description.abstractThe objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma. Treatment was doxorubicin 50 mg/m2 followed by a 24 h infusion of ifosfamide 5 g/m2 plus mesna 2.5 g/m2 repeated every 3 weeks until disease progression or unacceptable toxicity occurred. Of 203 patients entered, 175 were evaluable for response. The response rate was 35% (95% CI 28-42%), with 9% of the patients achieving a complete remission and 26% a partial remission. The median time to progression was 29 weeks for all evaluable patients, and 67, 40 and 28 weeks for complete and partial responders and patients with stable disease, respectively. The median duration of survival was 58 weeks. Myelosuppression was the dose-limiting toxicity, resulting in leukopenia (WHO grade 3 and 4) in 73% of evaluable treatment courses. Other side-effects were rare and usually well manageable.


This item appears in the following Collection(s)

Show simple item record